Europe Diabetic Foot Ulcer Treatment Market Size, Share & Trends Analysis Report By Treatment (Biologics, Wound Care Dressings), By Type (Neuro-Ischemic, Neuropathic), By End-use, By Country,- Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2025-2034

Europe Diabetic Foot Ulcer Treatment Market Size and Growth

The Europe diabetic foot ulcer treatment market size was exhibited at USD 1.85 billion in 2024 and is projected to hit around USD 3.18 billion by 2034, growing at a CAGR of 5.55% during the forecast period 2025 to 2034.

Europe Diabetic Foot Ulcer Treatment Market Key Takeaways:

• The neuro-ischemic ulcers segment held the largest market share of 53.10% in 2024 and is expected to continue its dominance over the forecast period.
• The neuropathic ulcer segment is expected to grow rapidly over the forecast period.
• The biologics segment dominated the market, with a 36.37% share in 2024.
• The therapy devices segment is expected to register the fastest CAGR from 2025 to 2034.
• The homecare segment accounted for a share of 52.85% in 2024 and is expected to grow fastest during the forecast period.

Report Scope of Europe Diabetic Foot Ulcer Treatment Market

Major factors contributing to the market growth include the increasing prevalence of foot ulcers among diabetes patients, increasing cases of ischemic ulcers, increasing number of diabetic patients vulnerable to diabetic injuries, a rise in the geriatric population, and technological advancements in diabetic foot management.

The increasing population of diabetic patients in Europe is significantly driving the market, as the rise in diabetes cases correlates with a higher incidence of foot ulcers. For instance, according to WHO,  diabetes is one of the most common long-term health issues in the European Region, and Europe has the highest rate of type 1 diabetes globally. By 2045, it is estimated that 1 in 10 people in the Region is expected to suffer from diabetes. Factors contributing to this rise include lifestyle changes, such as poor dietary habits and the aging population. The growing prevalence of diabetes poses significant challenges, leading to various complications such as foot ulcers and other neurological complications.

Rising number of geriatric population is also driving the market as aging population in Europe is contributing significantly to the rise in diabetes cases, as older adults are more prone to develop type 2 diabetes. As people live longer, the number of geriatric population is increasing, leading to a higher risk of diabetes-related complications, including diabetic foot ulcers. This trend creates a growing demand for effective treatments and care strategies tailored to older patients, further impacting the healthcare system and the market. For instance, according to the WHO, the number of people aged 60 and older in the European region was 215 million in 2021. This number is expected to grow to 247 million by 2030 and over 300 million by 2050.

Increasing investment in developing novel and advanced treatments for diabetic foot ulcers is also expected to drive market growth. For instance, In February 2021, the University of Bath initiated a Euro 1.7 million project to evaluate an innovative treatment for diabetic patients with foot ulcers. Funded by the National Institute for Health Research, this study intends to assess the efficacy of a pioneering approach that combines electrical stimulation with standard care protocols to promote wound healing. The initiative addresses the prevalent and serious complications associated with diabetes, mainly foot ulcers, which can result in severe health consequences, including the risk of amputation.

Europe Diabetic Foot Ulcer Treatment Market By Type Insights

The neuro-ischemic ulcers segment held the largest market share of 53.10% in 2024 and is expected to continue its dominance over the forecast period. Neuro-ischemic ulcers, which result from a combination of neuropathy and compromised blood flow, require specialized treatment approaches that often involve advanced wound care products and therapeutic devices. Innovations such as bioengineered tissues, growth factor therapies, and improved dressing materials are gaining popularity for enhancing healing in these challenging cases. In addition, integrating technologies such as vascular interventions and personalized treatment plans drives the demand for effective solutions in managing neuro-ischemic ulcers.

The neuropathic ulcer segment is expected to grow rapidly over the forecast period. The segment's growth is driven by the increasing prevalence of diabetes in Europe. This segment focuses on innovative therapies and products specifically designed for patients experiencing nerve damage and loss of sensation, leading to ulcer development. Leading aids include advanced wound care dressings, offloading devices, and therapeutic interventions such as growth factors and bioengineered skin substitutes. This segment is expected to witness significant expansion, fueled by heightened awareness of diabetic complications and ongoing advancements in treatment options.

Europe Diabetic Foot Ulcer Treatment Market By Treatment Insights

The biologics segment dominated the market, with a 36.37% share in 2024, owing to the high demand for biologicals in the treatment of diabetic foot. Biological therapies for diabetic foot ulcers leverage growth factors, skin substitutes, stem cell therapy, and collagen-based products to enhance healing by promoting angiogenesis, reducing inflammation, and stimulating cell proliferation. These treatments are particularly beneficial for chronic, non-healing wounds, potentially improving healing rates and reducing amputation risks. Challenges such as cost, accessibility, and variable patient responses remain. Thus, integrating biologicals with standard wound care and multidisciplinary approaches can significantly optimize patient outcomes.

The therapy devices segment is expected to register the fastest CAGR from 2025 to 2034. Therapy devices include NPWT, oxygen & hyperbaric oxygen equipment, electric stimulation devices, pressure relief devices, and other tools. These devices are particularly useful for chronic and hard-to-heal wounds, providing a non-invasive treatment option. The growing demand for non-invasive and patient-friendly treatment options is propelling the adoption of these devices in clinical settings. Challenges such as proper training, device accessibility, and patient compliance remain, necessitating ongoing advancements and education in this market. Thus, combining technological innovation and increasing awareness of effective wound care strategies positions the therapy device market for continued expansion in the coming years.

Europe Diabetic Foot Ulcer Treatment Market By End-use Insights

The homecare segment accounted for a share of 52.85% in 2024 and is expected to grow fastest during the forecast period. The growth of the segment can be attributed to several key factors. Primarily, it enhances patient comfort and convenience, fostering improved adherence to treatment protocols and yielding better clinical outcomes. In addition, homecare services are often more cost-effective than traditional hospital settings, significantly reducing the financial burden on patients and the healthcare system. Integrating telehealth technologies facilitates continuous monitoring and virtual consultations, essential for effectively managing DFUs. Also, these programs frequently include comprehensive education on wound care and diabetes self-management, empowering patients to participate actively in their treatment.

With the increasing prevalence of diabetes among the aging population, the demand for homecare solutions is expected to continue rising, reflecting a broader shift towards more patient-centered healthcare strategies. This personalized approach enables healthcare providers to customize treatment plans based on individual patient needs, optimizing healing and reducing the risk of complications.

Country Insights

UK Diabetic Foot Ulcer Treatment Market Trends

The diabetic foot ulcer treatment market in the UK held a significant share in 2024. The UK has a well-defined healthcare system consisting of advanced medical technologies for treating diabetic foot ulcers. The increasing prevalence of foot ulcers among diabetic patients in the UK is expected to drive the market's growth over the forecast period. For instance, in June 2022, NHS Resolution published a report on diabetes and lower limb complications, stating that 7957 cases of diabetes-induced lower limb amputations were recorded in the UK between 2017 and 2020.

Germany Diabetic Foot Ulcer Treatment Market Trends

The diabetic foot ulcer treatment market in Germany is expected to grow owing to the increasing recurrence of foot ulcers in diabetic patients in Germany. For instance, a study published in Diabetes Research and Clinical Practice Journal in December 2020 aimed to estimate the incidence of diabetic foot ulcer (DFU) recurrence and corresponding risk factors in Germany stated that the cumulative recurrence rate of diabetic foot ulcers (DFUs) was approximately 70% over 15 years. In Germany, 69% (154) of patients experienced at least one recurrence of DFU. The crude cumulative incidence of DFUs in the first year was 28% in this population.

France Diabetic Foot Ulcer Treatment Market Trends

The diabetic foot ulcer treatment market in France is expected to grow owing to technological advancements and the growing incidence of diabetic foot in the country. For instance, a study published in the Cardiovascular Diabetology Journal in February 2024 stated that in France, approximately 3.5 million individuals, representing 5.3% of the population, received treatment for diabetes in 2020. This statistic underscores the significant public health challenge posed by diabetes within the country.

Some of the prominent players in the Europe diabetic foot ulcer treatment market include:

• ConvaTec Group PLC
• Acelity L.P. Inc.
• 3M Health Care
• Coloplast Corp.
• Smith & Nephew Plc.
• B. Braun SE
• Medline Industries, LP
• Organogenesis, Inc.
• Molnlycke Health Care AB
• Medtronic.

Europe Diabetic Foot Ulcer Treatment Market Recent Developments 

• In October 2024, Molnlycke Health Care AB, a globally recognized leader in the MedTech sector specializing in wound care and management, announced the successful completion of the acquisition of P.G.F. Industry Solutions GmbH. P.G.F. Industry Solutions GmbH is well-known for its Granudacyn product line, specializing in advanced wound cleansing and moistening solutions.
  
  
• In January 2021, Smith & Nephew Plc., a global leader in medical technology, announced the completion of the acquisition of the Extremity Orthopaedics business from Integra LifeSciences Holdings Corporation for USD 240 million. This acquisition strategically aligns with the company’s objective to invest in higher-growth segments, significantly strengthening its extremities business by integrating a dedicated sales channel and a complementary portfolio of shoulder replacement and upper and lower extremities solutions.
  
  
• In January 2020, ConvaTec Group PLC, a prominent global medical technology company, announced the launch of ConvaMax, a new superabsorber dressing distributed by Convatec. The ConvaMax superabsorber wound dressing is designed to effectively manage exuding wounds, including leg ulcers, pressure ulcers, diabetic foot ulcers, and dehisced surgical wounds. 

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Europe diabetic foot ulcer treatment market

Treatment

• Wound Care Dressings
• Biologics
• Therapy Devices
• Antibiotic Medications
• Others

Type

• Neuropathic Ulcers
• Ischemic Ulcers
• Neuro-ischemic Ulcers

End-use Channel

• Hospitals and Clinics
• Ambulatory Surgical Centers
• Homecare (Others)

Country

• UK
• Germany6
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway